xGen Pan-Cancer Panel
105620516 rxn xGen Pan-Cancer Panel v1.516 rxn-α
105620496 rxn xGen Pan-Cancer Panel v1.596 rxn-α

xGen Pan-Cancer Panel

Enrich for genes implicated in several cancers

The xGen Pan-Cancer Panel v1.5 consists of 7816 xGen Lockdown Probes, spanning 800 kb of the human genome, for enrichment of 127 significantly mutated genes implicated across 12 tumor tissue types for deeper sequencing coverage.

  • Obtain high coverage uniformity across all targets
  • Detect variations reliably with high reproducibility and increased depth of coverage
  • Enjoy fast turnaround via easy online ordering and next day shipping

xGen Pan-Cancer Panel


16 rxn xGen Pan-Cancer Panel v1.5

96 rxn xGen Pan-Cancer Panel v1.5

Every year, ~500 people in every 100,000 are diagnosed with cancer. Of these, 34% will not survive past five years. Cancer resulted in more than 500,000 deaths in 2013 alone [1]. Next generation sequencing has enabled the discovery and characterization of gene-specific mutations that have the potential to be tumorigenic; however, the technology also implicates a large number of genes that are not relevant to an individuals cancerous state. A shortlist of mutated genes that are relevant to a multitude of cancer types, and that can be expanded to include additional cancer type–specific genes, would be invaluable in clinical and research applications. The Cancer Genome Atlas (TCGA) network performed a systematic analysis of more than 3000 tumors from 12 cancer types to investigate underlying mechanisms of cancer initiation and progression and have identified 127 significantly mutated genes (SMGs) across these tumor types [2].

The xGen Pan-Cancer Panel is a hybrid capture panel based on the findings of the TCGA network. The panel comprises xGen Lockdown Probes, individually synthesized and quality controlled 120mer oligonucleotides bearing a 5 biotin modification and manufactured using proprietary Ultramer synthesis technology.


  1. SEER Stat Fact Sheets: All Cancer Sites. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/statfacts/html/all.html. (Accessed Feb 2014.)
  2. Kandoth C, McLellan MD, et al. (2013) Mutational landscape and significance across 12 major cancer types. Nature, 502:333–339.


ıⰡ ϴ.
ı ۼ